Just how important is this scientific paper?

The most frequent alteration in the prostate oncogenome is loss of chromosome (chr) 8p21 that has been associated with loss of NKX3.1 homeobox gene.
… READ MORE …

Two Phase III trials of PARP inhibitors in mCRPC

There are now two, ongoing, Phase III trials of PARP inhibitors in the treatment of eligible patients with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

What we DON’T know from the ASCO abstracts …

Near the end of last month we had told you that data from the LATITUDE trial and from Arm G of the STAMPEDE trial would be presented at the ASCO annual meeting in Chicago this year. … READ MORE …

ASCO abstracts now available on line

The American Society for Clinical Oncology (ASCO) just released the abstracts for the hundreds of presentations and posters that will be given at the upcoming annual meeting of ASCO in June in Chicago. … READ MORE …

J&J expects to file for approval to market two new prostate cancer drugs

An announcement from Johnson & Johnson yesterday said that the company is projecting filings with regulatory authorities for approval of two new drugs for the treatment of advanced prostate cancer between 2017 and 2021. … READ MORE …

STAMPEDE group to present abiraterone survival data at ASCO too

We have just heard from the STAMPEDE trial group in the UK that they will be presenting overall survival data from the “abiraterone comparison” arm of the STAMPEDE trial at the upcoming ASCO meeting this year. … READ MORE …

Data from the LATITUDE trial to be presented at ASCO

According to an e-mail your sitemaster has just received from ASCO, we will be getting the initial results from the LATITUDE trial at the upcoming ASCO meeting in June this year. … READ MORE …